To profile adaptive responses in melanoma, we applied single-cell phenotypic and multiplex biochemical assays to nine BRAFV600E and one BRAFV600D lines exposed to four RAF inhibitors and one MEK inhibitor at multiple doses and times (Fig1A). Here, MAP2K7 is linked to melanoma.